Drug repurposing: Translational pharmacology, chemistry, computers and the clinic

Current Topics in Medicinal Chemistry

Volumn 13, Issue 18, 2013, Pages 2328-2336

  Issa, Naiem T ^a   Byers, Stephen W ^a,b   Dakshanamurthy, Sivanesan ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bioinformatics; Chemoinformatics; Clinical informatics; Drug discovery; Drug repositioning; Drug repurposing; High throughput screening; Network pharmacology; Phenotypic screening; Translational pharmacology

Indexed keywords

CORTICOSTEROID; IFENPRODIL TARTRATE; KETOCONAZOLE; MUSCARINIC M3 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NELFINAVIR; NUTLIN 3; RAPAMYCIN; SIMVASTATIN; STAUROSPORINE;

ARTICLE; BINDING SITE; BIOINFORMATICS; BREAST CANCER; CHEMOINFORMATICS; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; DRUG DESIGN; DRUG EFFICACY; DRUG REPOSITIONING; DRUG TARGETING; GENE EXPRESSION; HIGH PERFORMANCE COMPUTING; HIGH THROUGHPUT SCREENING; HUMAN; INFORMATION SCIENCE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PHARMACOLOGICAL SCIENCE; PREDICTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG REPOSITIONING; DRUG THERAPY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84887977891     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660163     Document Type: Article

References (75)

1. Ashburn, T. T.; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov, 2004, 3, 673-683.
2. Paul, S. M.; Mytelka, D. S.; Dunwiddie, C. T.; Persinger, C. C.; Munos, B. H.; Lindborg, S. R.; Schacht, A. L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov, 2010, 9, 203-214.
3. Huang, R.; Southall, N.; Wang, Y.; Yasgar, A.; Shinn, P.; Jadhav, A.; Nguyen, D. T.; Austin, C. P. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med, 2011, 3, 80ps16.
4. Collins, F. S. Mining for therapeutic gold. Nat. Rev. Drug Discov, 2011, 10, 397.
5. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ, 2003, 22, 151-185.
6. Hughes, B., 2007 FDA drug approvals: a year of flux. Nat. Rev. Drug Discov, 2008, 7, 107-109.
7. Lawrence, S. Drug output slows in, 2006. Nat. Biotechnol, 2007, 25, 1078.
8. Buehler, L. K. Advancing drug discovery-beyond design. Pharmacogenomics, 2004, 4, 24-26.
9. Wagner, B.; Kitami, T.; Gilbert, T.; Peck, D.; Ramanathan, A.; Schreiber, S.; Golub, T.; Mootha, V. Large-scale chemical dissection of mitochondrial function. Nat. Biotechnol, 2008, 26, 343-351.
10. Bajorath, J. Computational analysis of ligand relationships within target families. Curr. Opin. Chem. Biol, 2008, 12, 352-358.
11. Johnson, M. A.; Maggiora, G. M. Concepts and applications of molecular similarity; Wiley: New York, 1990.
12. Matter, H. Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and threedimensional molecular descriptors. J. Med. Chem, 1997, 40, 1219-1229.
13. Whittle, M.; Gillet, V. J.; Willett, P.; Alex, A.; Loesel, J. Enhancing the effectiveness of virtual screening by fusing nearest neighbor lists: a comparison of similarity coefficients. J. Chem. Inf. Comput. Sci, 2004, 44, 1840-1848.
14. Perez-Nueno, V. I.; Ritchie, D. W. Using consensus-shape clustering to identify promiscuous ligands and protein targets and to choose the right query for shape-based virtual screening. J. Chem. Inf. Model, 2011, 51, 1233-1248.
15. Warner, W. A.; Sanchez, R.; Dawoodian, A.; Li, E.; Momand, J. Identification of FDA-approved Drugs that Computationally Bind to MDM2. Chem. Biol. Drug Des, 2012, 80, 631-637.
16. Steindl, T. M.; Schuster, D.; Laggner, C.; Langer, T. Parallel screening: a novel concept in pharmacophore modeling and virtual screening. J. Chem. Inf. Model, 2006, 46, 2146-2157.
17. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol, 2007, 25, 197-206.
18. Willett, P. Searching techniques for databases of two-and threedimensional chemical structures. J. Med. Chem, 2005, 48, 4183-4199.
19. Paolini, G. V.; Shapland, R. H.; van Hoorn, W. P.; Mason, J. S.; Hopkins, A. L. Global mapping of pharmacological space. Nat. Biotechnol, 2006, 24, 805-815.
20. Vieth, M.; Higgs, R. E.; Robertson, D. H.; Shapiro, M.; Gragg, E. A.; Hemmerle, H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta, 2004, 1697, 243-257.
21. Izrailev, S.; Farnum, M. A. Enzyme classification by ligand binding. Proteins, 2004, 57, 711-724.
22. Bender, A.; Jenkins, J. L.; Glick, M.; Deng, Z.; Nettles, J. H.; Davies, J. W. "Bayes affinity fingerprints" improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept? J. Chem. Inf. Model, 2006, 46, 2445-2456.
23. Nidhi; Glick, M.; Davies, J. W.; Jenkins, J. L. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model, 2006, 46, 1124-1133.
24. Schuffenhauer, A.; Floersheim, P.; Acklin, P.; Jacoby, E. Similarity metrics for ligands reflecting the similarity of the target proteins. J. Chem. Inf. Comput. Sci, 2003, 43, 391-405.
25. Horvath, D.; Jeandenans, C. Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces-a novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles. J. Chem. Inf. Comput. Sci, 2003, 43, 680-690.
26. Bolton, E. E.; Chen, J.; Kim, S.; Han, L.; He, S.; Shi, W.; Simonyan, V.; Sun, Y.; Thiessen, P. A.; Wang, J.; Yu, B.; Zhang, J.; Bryant, S. H. PubChem3D: a new resource for scientists. J. Cheminform, 2011, 3, 32.
27. Lamb, J.; Crawford, E. D.; Peck, D.; Modell, J. W.; Blat, I. C.; Wrobel, M. J.; Lerner, J.; Brunet, J. P.; Subramanian, A.; Ross, K. N.; Reich, M.; Hieronymus, H.; Wei, G.; Armstrong, S. A.; Haggarty, S. J.; Clemons, P. A.; Wei, R.; Carr, S. A.; Lander, E. S.; Golub, T. R. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 2006, 313, 1929-1935.
28. Josset, L.; Textoris, J.; Loriod, B.; Ferraris, O.; Moules, V.; Lina, B.; N'guyen, C.; Diaz, J. J.; Rosa-Calatrava, M. Gene expression signature-based screening identifies new broadly effective influenza a antivirals. PLoS One, 2010, 5, e13169.
29. Cheng, T.; Li, Q.; Wang, Y.; Bryant, S. H. Identifying compoundtarget associations by combining bioactivity profile similarity search and public databases mining. J. Chem. Inf. Model, 2011, 51, 2440-2448.
30. Lounkine, E.; Keiser, M. J.; Whitebread, S.; Mikhailov, D.; Hamon, J.; Jenkins, J. L.; Lavan, P.; Weber, E.; Doak, A. K.; Cote, S.; Shoichet, B. K.; Urban, L. Large-scale prediction and testing of drug activity on side-effect targets. Nature, 2012, 486, 361-367.
31. Chen, M. H.; Yang, W. L.; Lin, K. T.; Liu, C. H.; Liu, Y. W.; Huang, K. W.; Chang, P. M.; Lai, J. M.; Hsu, C. N.; Chao, K. M.; Kao, C. Y.; Huang, C. Y. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. PLoS One, 2011, 6, e27186.
32. Sirota, M.; Dudley, J. T.; Kim, J.; Chiang, A. P.; Morgan, A. A.; Sweet-Cordero, A.; Sage, J.; Butte, A. J. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med, 2011, 3, 96ra77.
33. Oprea, T. I.; Nielsen, S. K.; Ursu, O.; Yang, J. J.; Taboureau, O.; Mathias, S. L.; Kouskoumvekaki, L.; Sklar, L. A.; Bologa, C. G. Associating Drugs, Targets and Clinical Outcomes into an Inte grated Network Affords a New Platform for Computer-Aided Drug Repurposing. Mol. Inform, 2011, 30, 100-111.
34. Scheiber, J.; Jenkins, J. L.; Sukuru, S. C.; Bender, A.; Mikhailov, D.; Milik, M.; Azzaoui, K.; Whitebread, S.; Hamon, J.; Urban, L.; Glick, M.; Davies, J. W. Mapping adverse drug reactions in chemical space. J. Med. Chem, 2009, 52, 3103-3107.
35. Laggner, C.; Kokel, D.; Setola, V.; Tolia, A.; Lin, H.; Irwin, J. J.; Keiser, M. J.; Cheung, C. Y.; Minor, D. L., Jr; Roth, B. L.; Peterson, R. T.; Shoichet, B. K. Chemical informatics and target identification in a zebrafish phenotypic screen. Nat. Chem. Biol, 2011, 8, 144-146.
36. Li, J.; Zhu, X.; Chen, J. Y. Building disease-specific drug-protein connectivity maps from molecular interaction networks and Pub-Med abstracts. PLoS Comput. Biol, 2009, 5, e1000450.
37. Iorio, F.; Bosotti, R.; Scacheri, E.; Belcastro, V.; Mithbaokar, P.; Ferriero, R.; Murino, L.; Tagliaferri, R.; Brunetti-Pierri, N.; Isacchi, A.; di Bernardo, D. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. USA, 2010, 107, 14621-14626.
38. Jin, G.; Fu, C.; Zhao, H.; Cui, K.; Chang, J.; Wong, S. T. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res, 2012, 72, 33-44.
39. DesJarlais, R. L.; Seibel, G. L.; Kuntz, I. D.; Furth, P. S.; Alvarez, J. C.; Ortiz de Montellano, P. R.; DeCamp, D. L.; Babe, L. M.; Craik, C. S. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc. Natl. Acad. Sci. USA, 1990, 87, 6644-6648.
40. Bohari, M. H.; Sastry, G. N. FDA approved drugs complexed to their targets: evaluating pose prediction accuracy of docking protocols. J. Mol. Model, 2012, 18, 4263-4274.
41. Bissantz, C.; Folkers, G.; Rognan, D. Protein based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J. Med. Chem, 2000, 43, 4759-4767.
42. Schulz-Gasch, T.; Stahl, M. Binding site characteristics in structure based virtual screening: Evaluation of current docking tools. J. Mol. Model, 2003, 9, 47-57.
43. Ferrara, P; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks, C. L. Assessing scoring functions for protein-ligand interactions. J. Med. Chem, 2004, 47, 3032-3047.
44. Kellenberger, E.; Rodrigo, J.; Muller, P.; Rognan, D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins Struct. Funct. Bioinf, 2004, 57, 225-242.
45. Englebienne, P.; Fiaux, H.; Kuntz, D. A.; Corbeil, C. R.; Gerber-Lemaire, S.; Rose, D. R.; Moitessier, N. Evaluation of docking programs for predicting binding of golgimannosidase II inhibitors: a comparison with crystallography. Proteins Struct. Funct. Bioinf, 2007, 69, 60-176.
46. Cross, J. B.; Thompson, D. C.; Rai, B. K. Comparison of several molecular docking programs: Pose prediction and virtual screening accuracy. J. Chem. Inf. Model, 2009, 49, 1455-1474.
47. Haupt, V. J.; Schroeder, M. Old friends in new guise: repositioning of known drugs with structural bioinformatics. Brief Bioinform, 2011, 12, 312-326.
48. Dakshanamurthy, S.; Issa, N. T.; Assefnia, S.; Seshasayee, A.; Peters, O. J.; Madhavan, S.; Uren, A.; Brown, M. L.; Byers, S. W. Predicting new indications for approved drugs using a proteochemometric method. J. Med. Chem, 2012, 55, 6832-6848.
49. Kinnings, S. L.; Liu, N.; Buchmeier, N.; Tonge, P. J.; Xie, L.; Bourne, P. E. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput. Biol, 2009, 5, e1000423.
50. Defranchi, E.; Schalon, C.; Messa, M.; Onofri, F.; Benfenati, F.; Rognan, D. Binding of protein kinase inhibitors to synapsin I inferred from pair-wise binding site similarity measurements. PLoS One, 2010, 5, e12214.
51. Pepin, J.; Milord, F.; Guern, C.; Schechter, P. J. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness. Lancet, 1987, 2, 1431-1433.
52. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discov, 2002, 1, 727-730.
53. Austin, C. P.; Battey, J. F.; Bradley, A.; Bucan, M.; Capecchi, M.; Collins, F. S.; Dove, W. F.; Duyk, G.; Dymecki, S.; Eppig, J. T.; Grieder, F. B.; Heintz, N.; Hicks, G.; Insel, T. R.; Joyner, A.; Koller, B. H.; Lloyd, K. C.; Magnuson, T.; Moore, M. W.; Nagy, A.; Pollock, J. D.; Roses, A. D.; Sands, A. T.; Seed, B.; Skarnes, W. C.; Snoddy, J.; Soriano, P.; Stewart, D. J.; Stewart, F.; Stillman, B.; Varmus, H.; Varticovski, L.; Verma, I. M.; Vogt, T. F.; von Melchner, H.; Witkowski, J.; Woychik, R. P.; Wurst, W.; Yancopoulos, G. D.; Young, S. G.; Zambrowicz, B. The knockout mouse project. Nat. Genet, 2004, 36, 921-924.
54. Zambrowicz, B. P.; Sands, A. T. Knockouts model the 100 bestselling drugs--will they model the next 100? Nat. Rev. Drug Discov, 2003, 2, 38-51.
55. Zambrowicz, B. P.; Turner, C. A.; Sands, A. T. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr. Opin. Pharmacol, 2003, 3, 563-570.
56. Barabasi, A. L.; Oltvai, Z. N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet, 2004, 5, 101-113.
57. Albert, R.; Jeong, H.; Barabasi, A. L. Error and attack tolerance of complex networks. Nature, 2000, 406, 378-382.
58. Chen, Y.; Zhu, J.; Lum, P. Y.; Yang, X.; Pinto, S.; MacNeil, D. J.; Zhang, C.; Lamb, J.; Edwards, S.; Sieberts, S. K.; Leonardson, A.; Castellini, L. W.; Wang, S.; Champy, M. F.; Zhang, B.; Emilsson, V.; Doss, S.; Ghazalpour, A.; Horvath, S.; Drake, T. A.; Lusis, A. J.; Schadt, E. E. Variations in DNA elucidate molecular networks that cause disease. Nature, 2008, 452, 429-435.
59. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multitarget drugs: the network approach might help drug design. Trends Pharmacol. Sci, 2005, 26, 178-182.
60. Korcsmaros, T.; Szalay, M. S.; Bode, C.; Kovacs, I.; Csermely, P. How to design multi-target drugs: target search options in cellular networks. Expert Opin. Drug Discov, 2007, 2, 1-10.
61. Liang, D.; Han, G.; Feng, X.; Sun, J.; Duan, Y.; Lei, H. Concerted perturbation observed in a hub network in Alzheimer's disease. PLoS One, 2012, 7, e40498.
62. Elgoyhen, A. B.; Langguth, B.; Vanneste, S.; De Ridder, D. Tinnitus: network pathophysiology-network pharmacology. Front. Syst. Neurosci, 2012, 6, 1.
63. Chu, L. H.; Chen, B. S. Construction of a cancer-perturbed proteinprotein interaction network for discovery of apoptosis drug targets. BMC Syst. Biol, 2008, 2, 56.
64. Cheng, F.; Liu, C.; Jiang, J.; Lu, W.; Li, W.; Liu, G.; Zhou, W.; Huang, J.; Tang, Y. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput. Biol, 2012, 8, e1002503.
65. Campillos, M.; Kuhn, M.; Gavin, A. C.; Jensen, L. J.; Bork, P. Drug target identification using side-effect similarity. Science, 2008, 321, 263-266.
66. Zhang, A.; Sun, H.; Yang, B.; Wang, X. Predicting new molecular targets for rhein using network pharmacology. BMC Syst. Biol, 2012, 6, 20.
67. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. Predicting new molecular targets for known drugs. Nature, 2009, 462, 175-181.
68. Xie, L.; Evangelidis, T.; Xie, L.; Bourne, P. E. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput. Biol, 2011, 7, e1002037.
69. von Eichborn, J.; Murgueitio, M. S.; Dunkel, M.; Koerner, S.; Bourne, P. E.; Preissner, R. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res, 2011, 39, D1060-6.
70. Chow, W. A.; Jiang, C.; Guan, M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol, 2009, 10, 61-71.
71. Gills, J. J.; Lopiccolo, J.; Tsurutani, J.; Shoemaker, R. H.; Best, C. J.; Abu-Asab, M. S.; Borojerdi, J.; Warfel, N. A.; Gardner, E. R.; Danish, M.; Hollander, M. C.; Kawabata, S.; Tsokos, M.; Figg, W. D.; Steeg, P. S.; Dennis, P. A. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin. Cancer Res, 2007, 13, 5183-5194.
72. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A., Jr; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321, 1807-1812.
73. Jones, S.; Zhang, X.; Parsons, D. W.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S. M.; Fu, B.; Lin, M. T.; Calhoun, E. S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D. R.; Hidalgo, M.; Leach, S. D.; Klein, A. P.; Jaffee, E. M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J. R.; Kern, S. E.; Hruban, R. H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 2008, 321, 1801-1806.
74. Shim, J. S.; Rao, R.; Beebe, K.; Neckers, L.; Han, I.; Nahta, R.; Liu, J. O. Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir. J. Natl. Cancer Inst, 2012, 104, 1576-1590.
75. Gottlieb, A.; Stein, G. Y.; Ruppin, E.; Sharan, R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol, 2011, 7, 496.